Clostridioides difficile Infection (CDI) is a leading cause of healthcare-associated infections in Canada, affecting the gastrointestinal tract which can lead to fever, abdominal pain, and diarrhea. Effective treatment for patients with Recurrent CDI (rCDI) can be achieved by Fecal Microbiota Transplantation (FMT) by introducing the gut micro-organisms of a healthy person (donor) into the bowel of the affected individual. Research has shown that an increase in the specific bacterial phyla post-FMT may be partly responsible for this gut restoration and elimination of disease. Furthermore, in understanding the key bacteria associated with successful FMT, full treatment plans can be developed for the individual needs of the patient by matching an infected individual with a donor possessing ideal microbiota for the specific patient. This development of precision medicine and more systematic adoption of FMT can be the next step toward more rapid resolution of rCDI.
Get full access to this article
View all access options for this article.
References
1.
DyerCHuttLBurkyR, et al.Biocide resistance and transmission of Clostridium difficile spores spiked onto clinical surfaces from an American healthcare facility. Appl Environ Microbiol. 2019;85(17):e01090–19. doi:10.1128/AEM.01090-19.
2.
RagusaRGiorgianniGLupoL, et al.Healthcare-associated Clostridium difficile infection: role of correct hand hygiene in cross-infection control. J Prev Med Hyg. 2018;59(2):145–152.
3.
PetrofEGloorTVannerS, et al.Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013;1(3):1–12.
4.
LeslieJVendrovKJeniorMYoungVB. The gut microbiota is associated with clearance of Clostridium difficile infection independent of adaptive immunity. mSphere. 2019;4(1):
1–12.
5.
KhannaSPardiDKellyC, et al.A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridioides difficile infection. J Infect Dis. 2016;214(2):173–181.
6.
JalankaJMattilaEJouhtenH, et al.Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in feacal microbiota transplantation for recurrent Clostridioides difficile infection. BMC Med. 2016;14(1):1–8.
7.
LeeCKimPSmithE. Outcome of fecal microbiota transplatation for recurrent Clostridium difficile infection on quality of life. Gastroenterology. 2017;152(5):S949.
8.
FuentesSVan NoodETimsS, et al.Reset of critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridioides difficile infection. ISME J. 2014;8(8):1621–1633.
9.
DicksonGBriscoeDFenwickS, et al.The Pan-Canadian Health Leadership Capability Framework Project: a Collaborative Research Initiative to Develop a Leadership Capability Framework for Healthcare in Canada. Ottawa, Ontario, Canada: Canadian Health Services Research Foundation; 2007.
10.
CarlucciCJonesCOliphantK, et al.Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile. Sci Rep. 2019;9(1):885. doi:10.1038/s41598-018-37547-x.
11.
ShankarVHamiltonMKhorutsA, et al.Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014;2:13–23.
12.
StaleyCKellyCBrandtL, et al.Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. mBio. 2016;7(6):e01965.
13.
BroekerFKlumppJMoellingK. Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection. Ann N Y Acad Sci. 2016;1372(1):29–41.
14.
ReaK. Colonization potential to reconstitute a microbe community in patients detected early after fecal microbe transplant for recurrent C. difficile. BMC Microbiol. 2016;16(4):1–9.
15.
SamarkosMMastrogianniEKampouropoulouO. The role of gut microbiota in Clostridium difficile infection. Eur J Intern Med. 2018;50:28–32.
16.
LeeCSteinerTPetrofE, et al.Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection a randomized clinical trial. JAMA. 2016;315(2):142–149.
17.
HaysRMoralesL. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33(5):350–357.
18.
Lapointe-ShawLTranKCoyteP, et al.Cost-effectiveness analysis of six strategies to treat recurrent Clostridium difficile infection. PLoS One. 2016;11(2):e0149521.
19.
VarierRBiltajiESmithK, et al.Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2015;36(4):438–444.
20.
KarimiMBrazierJ. Health, health-related quality of life, and quality of life: what’s the difference?Pharmacoeconomics. 2016;34(7):645–649.
21.
BrandtLAroniadisOMellowM, et al.Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079–1087.
22.
KaoDRoachBSilvaM, et al.Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318(20):1985–1993.
23.
LeeCChaiJHammondK, et al.Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure. Eur J Clin Microbiol Infect Dis. 2019;38(9):1731–1735. doi:10.1007/s10096-019-03602-2.
24.
LeeCRushSWeeseJ, et al.Engraftment and augmentation of microbiome following fecal microbiota transplantation for recurrent Clostridium difficile infection. Open Forum Infect Dis. 2017;4(suppl 1):S380–S381.
